Wegovy Pill May Expand Access to Obesity Treatments

The United States Food and Drug Administration has greenlit the initial tablet form of a GLP-1 drug designed for shedding pounds, which might considerably broaden availability of obesity therapies. Produced by the Danish firm Novo Nordisk, this daily Wegovy pill is set to debut in early January, with clinical trial participants averaging a 16.6% drop in body weight.

The United States Food and Drug Administration has granted approval for the initial oral form of a GLP-1 medication intended for weight reduction, a step that could substantially broaden the reach of obesity therapies.

Produced by the Danish pharmaceutical company Novo Nordisk, the once-daily Wegovy tablet is slated to become available in early January. Novo Nordisk reports that individuals participating in clinical studies who used the Wegovy pill experienced an average loss of 16.6% in their total body weight.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Health tracking applications such as Shotlee can assist users in monitoring their progress during weight loss journeys when combined with these treatments.

Source Information

Originally published by Owensboro Messenger-Inquirer.Read the original article →

Keep exploring

More on Wegovy

Articles covering Wegovy dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Obesity

All Obesity articles →

Pharmaceutical Industry News

Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics

Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.

8 min read

Weight Management

Semaglutide for Weight Loss in Adults Over 65: New Study Findings

A recent analysis of the STEP trials reveals that semaglutide, the active ingredient in popular medications like Ozempic and Wegovy, offers significant weight loss and health benefits for adults over 65 with obesity, with a safety profile comparable to younger populations.

8 min read

Health

Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter

Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.

8 min read

More in Health

Health

Ozempic 2.0? Exploring the Future of Weight Loss Medications

New weight loss drugs, potentially available in oral form, are under development by Eli Lilly and Novo Nordisk. These medications aim to manage type-2 diabetes and facilitate weight loss, potentially offering a more accessible and convenient alternative to current injectables.

4 min read

Health

Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race

With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.

7 min read

Health

Mounjaro Weight-Loss Injection Now Top-Selling Drug in India

According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.

3 min read